Allianz Asset Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Allianz Asset Management’s Portfolio ECYT Stock Details ECYT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-165,528	Closed	-$2.94M	–	2768
2018 Q3	$2.94M	Buy	165,528 +17,129	+12%	+$294K	﹤0.01%	1805
2018 Q2	$2.05M	Buy	+148,399	New	+$1.76M	﹤0.01%	1934
2014 Q2	–	Sell	-94,687	Closed	-$2.25M	–	2031
2014 Q1	$2.25M	Sell	94,687 -5,674	-6%	-$82.3K	﹤0.01%	1173
2013 Q4	$1.07M	Sell	100,361 -5,734	-5%	-$63.3K	﹤0.01%	1383
2013 Q3	$1.41M	Buy	106,095 +4,895	+5%	+$77.4K	﹤0.01%	1291
2013 Q2	$1.33M	Buy	+101,200	New	+$1.36M	﹤0.01%	1287

Other funds holding ECYT

OTC

Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return

Claro Advisors Boston, Massachusetts $953M AUM 24.79% 1-Year Est. Return

Allianz Asset Management's ECYT Position: Q4 2018 in Review

Allianz Asset Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q4 2018, closing a stake of 165,528 shares — an estimated $2.94M sold.

Allianz Asset Management first reported a position in ECYT in Q2 2013 and held it in 6 quarters. The position peaked at $2.94M in Q3 2018. 2 funds tracked by Wall St. Rank hold ECYT as of Q4 2018.

Allianz Asset Management reported no remaining Endocyte, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Allianz Asset Management sold 165,528 Endocyte, Inc. Common Stock shares in Q4 2018, an estimated $2.94M.
Allianz Asset Management first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
Allianz Asset Management's Endocyte, Inc. Common Stock position peaked at $2.94M in Q3 2018.
2 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q4 2018.

Based on Allianz Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.